![Naval Daver presents findings of the ENHANCE-3 study at EHA2024 – AML Hub](https://oncodaily.com/pub/uploads/2024/06/GQHdSVGXgAAnOv5-1280x716.jpeg)
Photo taken from AML Hub/X
Jun 19, 2024, 07:28
Naval Daver presents findings of the ENHANCE-3 study at EHA2024 – AML Hub
AML Hub shared the following post on X: .
“CONGRESS EHA2024 | Naval Daver
MD Anderson Cancer Center presents findings of the phase III ENHANCE-3 study (NCT05079230) evaluating efficacy and safety of magrolimab (vs placebo) in combination with azacitidine and venetoclax in pts with previously untreated AML ineligible for IC (N=378). Magrolimab, in comparison with placebo, led to:
- longer mOS (10.7 vs 14.1 mo, respectively),
- more deaths (44.4% vs 37.0%, respectively),
- similar CR rate within 6 cycles of treatment (41.3% vs 46.0%, respectively), and
- increased incidence of fatal AEs (19% vs 11.4%, respectively) and infections (11.1% vs 6.5%, respectively).
The study was stopped early due to crossing the prespecified futility boundary for OS.”
Source: AML Hub/X